Navigating the wealth of information—and misinformation—about bromhexine and other potential COVID-19 treatments can be overwhelming. This FAQ draws on current research and expert perspectives to answer your most pressing questions, with a special focus on studies that sit outside the mainstream headlines. Whether you are a healthcare professional, a patient, or simply a curious reader, we hope this guide provides clarity and context for the ongoing scientific conversation.
What is bromhexine, and why is it being investigated for COVID-19?
Bromhexine is a mucolytic agent that has been used for decades to treat respiratory conditions associated with thick mucus, such as chronic bronchitis and cystic fibrosis. It works by breaking down the structure of mucus, making it easier to cough up and clear the airways. In some countries, it is available over the counter, while in others it requires a prescription.
Its potential role in COVID-19 stems from an entirely different property: the ability to inhibit a host enzyme called transmembrane protease serine 2 (TMPRSS2). SARS-CoV-2, the virus that causes COVID-19, relies on TMPRSS2 to prime its spike protein after binding to the ACE2 receptor on human cells. Without this priming step, the virus cannot fuse with the cell membrane and deliver its genetic material. By blocking TMPRSS2, bromhexine—and its active metabolite ambroxol—may reduce viral entry and replication. This mechanism was first highlighted in a 2020 study that used cell cultures and has since spurred several clinical investigations.
How strong is the evidence supporting bromhexine’s use against COVID-19?
The evidence base for bromhexine as a COVID-19 treatment is mixed and largely consists of small-scale studies, observational analyses, and a handful of randomised controlled trials (RCTs). A notable double-blind, placebo-controlled trial from Iran suggested that bromhexine could reduce intensive care unit admissions and mortality when given to hospitalised patients with moderate-to-severe disease. However, this study was relatively small, with just over 100 participants, and has not been replicated at a larger scale.
Other studies have yielded less promising results. For example, a multicentre trial in Brazil found no significant benefit of bromhexine in preventing hospitalisation or reducing symptom duration among high-risk outpatients. The differing outcomes may reflect variations in dosing, timing of administration, patient populations, and study design. As of early 2025, no major regulatory agency has approved bromhexine for COVID-19, and most guidelines advise against its routine use outside of clinical trials.
Despite the lack of definitive evidence, bromhexine continues to attract interest because of its strong safety profile, low cost, and widespread availability. It remains a candidate worth watching, but patients and clinicians should interpret the current research with caution and avoid using it as a substitute for proven therapies.
“The story of bromhexine is a classic example of repurposing an old drug for a new disease—promising in theory, challenging in practice, and needing much more rigorous testing before we can draw firm conclusions.” — A sentiment echoed by many clinical pharmacologists.
What other repurposed drugs have been studied for COVID-19, and what have we learned?
The search for effective COVID-19 treatments led researchers to test hundreds of existing medications. Some of the most widely publicised include hydroxychloroquine, ivermectin, remdesivir, and dexamethasone. Each has a distinct mechanism and a varying degree of clinical success.
Hydroxychloroquine, an antimalarial and immunomodulatory drug, showed early in vitro activity against SARS-CoV-2 but failed to demonstrate consistent clinical benefit in large RCTs. It is now generally not recommended for COVID-19. Ivermectin, an antiparasitic agent, also attracted significant attention after laboratory studies suggested antiviral properties. However, well-designed trials, including the important López-Medina: Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19, found no significant effect on symptom resolution or hospitalisation. This study, conducted in Colombia, was a double-blind, placebo-controlled RCT that contributed to the evolving consensus against the routine use of ivermectin for COVID-19.
Remdesivir, an antiviral originally developed for Ebola, received emergency use authorisation from multiple regulators after trials showed it could modestly shorten recovery time in hospitalised patients. Meanwhile, dexamethasone, a cheap corticosteroid, proved to be a game-changer for severely ill patients by reducing mortality from cytokine storm. These examples illustrate that while repurposing can succeed, it requires rigorous testing to separate truly effective therapies from false leads.
Why does research on COVID-19 treatments often seem contradictory?
Conflicting results are not unusual in medical research, but the speed and volume of COVID-19 studies have amplified the problem. During the pandemic, thousands of trials were launched simultaneously, often with small sample sizes and varying methodologies. This led to what some scientists call “research waste”—studies that were too underpowered or poorly designed to provide meaningful answers.
Additional factors include publication bias (negative results are less likely to be published), differences in patient demographics, and the rapid evolution of the virus itself. As new variants emerged, drugs that seemed promising against the original strain sometimes lost efficacy. The standard of care also changed over time, complicating comparisons between early and late trials. For the public, these shifts can be frustrating, but they are a natural part of the scientific process. Reliable knowledge is built through cumulative evidence, not single studies.
How can I tell if a study about a COVID-19 treatment is trustworthy?
Evaluating medical research requires looking beyond headlines and press releases. Key questions to ask include: Was the study randomised and placebo-controlled? How many participants were included? Was the outcome clinically meaningful (e.g., mortality, hospitalisation) rather than just a laboratory measurement? Was the study peer-reviewed and published in a reputable journal?
It is also important to check for conflicts of interest. Researchers or sponsors with financial stakes may unconsciously—or consciously—bias the analysis. Open-access data and pre-registration of trial protocols are signs of transparency. Tools like the Cochrane risk-of-bias assessment can help, but for the average reader, relying on systematic reviews and meta-analyses from respected organisations is often the safest approach. Be wary of anecdotal evidence and social media claims, no matter how compelling they seem.
What should I consider before using bromhexine or any off-label treatment for COVID-19?
Off-label use means prescribing a drug for a condition or at a dose not specifically approved by regulators. While common in medicine, it carries additional risks, especially when the evidence base is thin. Anyone considering bromhexine for COVID-19 should have an in-depth discussion with a healthcare provider. Factors to weigh include the patient’s overall health, disease severity, potential drug interactions, and the availability of proven alternatives.
In many cases, the best defence against severe COVID-19 remains vaccination, along with antivirals like nirmatrelvir/ritonavir (Paxlovid) that have strong trial support. Bromhexine is not a substitute for these measures. If you do decide to use it, ensure you are obtaining it from a legitimate source and that your doctor is monitoring you for any adverse effects, even though they are rare.
Where can I find reliable updates on bromhexine and other emerging COVID-19 research?
Staying informed is crucial, but the information landscape is cluttered. Prioritise sources that aggregate and critically appraise evidence. The World Health Organization’s (WHO) COVID-19 research database, the Cochrane Library, and NIH treatment guidelines are excellent starting points. For bromhexine specifically, PubMed and clinical trial registries like ClinicalTrials.gov can provide the latest study results.
We also recommend following reputable medical journals—The Lancet, The New England Journal of Medicine, JAMA—which usually publish thoroughly vetted research. Avoid relying on single blogs or social media personalities, no matter how confident they sound. Science is a collective, self-correcting endeavour, and patience is often required for the truth to emerge.